Trends of Antihypertensive, Antidiabetic, and Nonsteroidal Anti-Inflammatory Drugs Use among the Health Workers Cohort Study, Mexico 2004 to 2018
Table 2
Percentage and 95% CI of utilization of each drug across the three assessments.
Drug
2004–2006
2010–2013
2017-2018
Percentage
CI 95%
Percentage
CI 95%
Percentage
CI 95%
Antihypertensive
ACE-I
44.8%
41.7–47.9
38.1%
34.1–42.2
23.0%
18.8–27.8
ARB II
8.0%
6.5–9.9
15.5%
12.7–18.8
22.7%
18.5–27.5
CCB
23.2%
20.7–26.0
15.3%
12.6–18.6
4.7%
2.9–7.6
B-blocker
26.7%
23.9–29.5
55.4%
51.2–59.5
74.6%
69.7–79.0
TD
35.0%
32.0–38.0
22.9%
19.6–26.6
19.5%
15.6–24.1
Antidiabetic
Metformin
9.5%
6.8–13.0
74.2%
68.4–79.3
83.9%
79.4–87.6
Glibenclamide
97.8%
95.6–98.9
52.0%
45.8–58.1
21.1%
16.9–26.0
Sitagliptin
0.9%
0.3–2.9
NSAIDs
Anti-inflammatories
16.0%
15.3–16.7
17.0%
15.7–18.4
13.9%
12.1–15.9
Acetylsalicylic acid
14.1%
13.4–14.8
12.9%
11.8–14.2
12.2%
10.5–14.1
Acetaminophen
2.9%
2.6–3.3
2.2%
1.7–2.7
1.8%
1.2–2.7
ACE-I, angiotensin-converting enzyme inhibitor; ARB II, angiotensin II receptor blockers; CCB, calcium channel blockers; B-blocker, beta-blockers; TD, thiazide diuretics; NSAID, nonsteroidal anti-inflammatory drug. Estimates of proportions, standard errors, and 95% CI were made by the values in each drug category.
